Verastem, Inc. (NASDAQ: VSTM) shares gained about 6.4% to $8.25 on Wednesday, making it one of the top performers in the PRISM Women’s Health Index….
October 07, 2026
Zura Bio Shares Climb 9% as Hidradenitis Suppurativa Data Takes Center Stage Ahead of Its Q4 Readout
Zura Bio Limited (NASDAQ: ZURA) shares rose about 9.5% to $4.34 on Wednesday, making it the top gainer in the PRISM Biotech Index. The move…
September 29, 2026
Summit Therapeutics Lands $2 Billion From AstraZeneca — at a Premium, Not a Discount
Summit Therapeutics (SMMT) shares jumped roughly 25% in premarket trade Tuesday after AstraZeneca (AZN) agreed to invest $2 billion in the clinical-stage oncology company and…
September 24, 2026
Satellos Bioscience Clears FDA Hurdle for Second Indication — and Funds It Without Dilution
Satellos Bioscience (MSLE) announced Thursday that the US Food and Drug Administration cleared its Investigational New Drug application for forazapadin in facioscapulohumeral muscular dystrophy, opening…
September 23, 2026
Viking Therapeutics Shares Jump 36% After New Obesity Data Shows Patients Keep the Weight Off
Viking Therapeutics (Nasdaq: VKTX) shares rose 35.7% to close at $40.85 on Tuesday. The rally followed new clinical data for VK2735, the company’s experimental weekly…
September 21, 2026
Xenon Pharmaceuticals Sheds 31% as a Psychosis Signal Pauses Two Phase 3 Depression Trials
Xenon Pharmaceuticals (NASDAQ: XENE) delivered good news and bad news in the same press release — and investors priced only the bad. The company submitted…
September 15, 2026
GSK Bets Up to $750 Million on Chimagen Blood Cancer Therapy to Deepen Its Oncology Push
GSK (GSK) moved decisively to strengthen its blood-cancer franchise on Tuesday, agreeing to acquire global rights to an experimental multiple myeloma therapy from Chinese biotech…
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) cleared a key genetic engineering milestone for Bria-MEL+™, its personalized whole-cell melanoma immunotherapy vaccine candidate. The clinical-stage…
AbCellera Biologics (ABCL) ripped higher Monday, jumping more than 30% to about $9.07, after the biotech reported positive top-line Phase 2 results for its lead…
Shares of ImmunityBio, Inc. (NASDAQ: IBRX) jumped roughly 7.5% after the Emirates Drug Establishment (EDE) granted Marketing Authorization for ANKTIVA® (nogapendekin alfa inbakicept) across two…
July 29, 2026
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ: CAPR) announced that The Lancet has published results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the company’s investigational cell therapy…
Forte Biosciences (FBRX) shares rocketed higher Monday after the company agreed to sell itself to Belgian-Dutch immunology specialist argenx (ARGX) in a deal valued at…